

# UC Irvine

## UC Irvine Previously Published Works

### Title

Meta-analysis of cognitive ability differences by apolipoprotein e genotype in young humans.

### Permalink

<https://escholarship.org/uc/item/9z26k9rn>

### Authors

Weissberger, Gali H  
Nation, Daniel A  
Nguyen, Caroline P  
et al.

### Publication Date

2018-11-01

### DOI

10.1016/j.neubiorev.2018.08.009

Peer reviewed



# HHS Public Access

Author manuscript

*Neurosci Biobehav Rev.* Author manuscript; available in PMC 2019 November 01.

Published in final edited form as:

*Neurosci Biobehav Rev.* 2018 November ; 94: 49–58. doi:10.1016/j.neubiorev.2018.08.009.

## Meta-analysis of cognitive ability differences by apolipoprotein e genotype in young humans

Gali H. Weissberger<sup>a,\*</sup>, Daniel A. Nation<sup>b</sup>, Caroline P. Nguyen<sup>a</sup>, Mark W. Bondi<sup>c</sup>, and S. Duke Han<sup>a,b,d,e</sup>

<sup>a</sup>Department of Family Medicine, USC Keck School of Medicine, 1000 S. Fremont Avenue, Unit 22, HSA Building A-6, 4thFloor, Room 6437A, Alhambra, CA, 91803, USA

<sup>b</sup>Department of Psychology, USC Dornsife College of Letters, Arts, and Sciences, Los Angeles, 90089, CA, USA

<sup>c</sup>Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive #9116-B, La Jolla, CA, 92093, USA

<sup>d</sup>USC School of Gerontology, Los Angeles, CA, 90089, USA

<sup>e</sup>Department of Neurology, USC Keck School of Medicine, Los Angeles, 90033, CA, USA

### Abstract

The apolipoprotein (APOE)  $\epsilon 4$  allele has been proposed as an example of an antagonistic pleiotropy gene, conferring a beneficial effect on cognition in early life and a detrimental impact on cognition during later years. However, findings on the cognitive associations of the  $\epsilon 4$  allele in younger persons are mixed. This PRISMA conforming study aimed to investigate APOE genotype ( $\epsilon 4$ /non- $\epsilon 4$ ) associations across seven cognitive domains (intelligence/achievement, attention/working memory, executive functioning, memory, language, processing speed and visuospatial abilities) in younger humans using a meta-analytic approach. Of 689 records reviewed, 29 studies (34 data-points) were selected for the quantitative synthesis. Participants' ages ranged from 2-40. Results showed that young  $\epsilon 4$  carriers did not statistically differ from non- $\epsilon 4$  carriers across any cognitive domains. Overall, findings do not provide compelling support for an antagonistic pleiotropic effect of the  $\epsilon 4$  allele across the lifespan.

### Keywords

Apolipoprotein E; Alzheimer's disease; Cognition; Neuropsychology; Executive functions; PRISMA

---

\*Corresponding author. Gali.Weissberger@med.usc.edu (G.H. Weissberger).

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.neubiorev.2018.08.009>.

## 1. Introduction

The link between the apolipoprotein (APOE)  $\epsilon 4$  allele and Alzheimer's disease (AD) is well established in the literature (Farrer et al., 1997; Saunders et al., 1993). Presence of the APOE  $\epsilon 4$  allele confers a three- to four-fold increased risk of developing Alzheimer's disease (AD; Saunders et al., 1993) and has been linked to neuropathological changes associated with AD, including beta-amyloid plaques (Morris et al., 2010; Serrano-Pozo et al., 2015; Strittmatter et al., 1993) and neurofibrillary tangles (Namba et al., 1991). Furthermore, presence of the  $\epsilon 4$  allele in healthy non-demented older adults is associated with poorer cognitive performance (Bondi et al., 1995; Caselli et al., 2004; Small et al., 2004), reduced grey matter volume in regions associated with AD (Den Heijer et al., 2002; Scarmeas and Stern, 2006; Soininen et al., 1995), and differences in cerebral activity during resting and task-based functional magnetic resonance imaging (fMRI; e.g., Bondi et al., 2005; Bookheimer et al., 2000; Tuminello and Han, 2011 for review) compared to non-demented older adults without the allele.

In recent years, there has been increased interest in understanding the effect of the APOE  $\epsilon 4$  allele on cognition in different age groups, including children and young adults. Findings support differential effects of the  $\epsilon 4$  allele on cognition based on the age group under investigation. Compared to healthy older adults in whom cognitive deficits have been consistently reported in  $\epsilon 4$  carriers (Small et al., 2004), differences between  $\epsilon 4$  and non- $\epsilon 4$  carriers in middle age are reduced or null (Salvato, 2015 for review). Conversely, in young adults and children, some studies report  $\epsilon 4$  carriers outperforming non- $\epsilon 4$  carriers on cognitive tasks (Han and Bondi, 2008 for review).

Based on findings suggesting differential cognitive effects of  $\epsilon 4$  allele possession throughout the lifespan, Han and Bondi (2008) along with others (Alexander et al., 2007; Jochemsen et al., 2012; Rusted et al., 2013) proposed the antagonistic pleiotropy hypothesis of APOE  $\epsilon 4$ . Antagonistic pleiotropy is a theory of senescence in which "individual loci/alleles have different effects on fitness at different ages" (Albin, 1993; Williams, 2001). Specifically, these alleles are thought to have a positive, beneficial effect on fitness in early life and a negative, detrimental impact on fitness during later years in the context of aging (Albin, 1993). Han and Bondi (2008) suggested that  $\epsilon 4$  is one such allele, conferring advantages on cognitive tasks early in life but resulting in cognitive and neural disadvantages in late life. Although this is theoretically compelling, findings regarding cognition in younger  $\epsilon 4$  carriers are mixed. While some studies provide support for better cognition in young  $\epsilon 4$  carriers compared to non- $\epsilon 4$  carriers (Bloss et al., 2010; Puttonen et al., 2003; Schultz et al., 2008; Wright et al., 2003; Yu et al., 2000), other studies fail to find support (Deary et al., 2003; Dennis et al., 2010; Filbey et al., 2006; Jorm et al., 2007; Luciano et al., 2009; Richter-Schmidinger et al., 2011) and some even report poorer cognitive performances in young  $\epsilon 4$  carriers (Acevedo et al., 2010; Bloss et al., 2008; Calderon-Garciduenas et al., 2016).

Mixed findings regarding cognitive effects of the  $\epsilon 4$  allele in younger persons likely relate to methodological variability between research studies. In a review of the literature, Tuminello and Han (2011) discuss the implications of some studies including high-risk groups in their

samples and suggest that accounting for additional variables that can affect cognition is an important factor that can impact study results. For example, other AD risk factors such as family history of AD (e.g., see Bloss et al., 2008) and presence of other AD-related genes (e.g., Green et al., 2014) may interact with APOE genotype to impact cognition. Additionally, studies vary with regards to their definition of young  $\epsilon 4$  and non- $\epsilon 4$  carriers, with some examining very wide age ranges (e.g., Stening et al., 2016; Suri et al., 2015) and others including restricted ranges (Bunce et al., 2011, 2014; Dell'Acqua et al., 2015). This can potentially be an important source of variability if the  $\epsilon 4$  allele exerts a beneficial effect on cognition during a restricted time period in early life (Tuminello and Han, 2011).

An additional source of variability between studies is classification of  $\epsilon 4$  and non- $\epsilon 4$  participants. While some studies exclude  $\epsilon 4$  carriers who also possess the  $\epsilon 2$  allele (e.g., Calderon-Garciduenas et al., 2016; Dennis et al., 2010; Filbey et al., 2006; Jorm et al., 2007), others do not (e.g., Acevedo et al., 2010; Luciano et al., 2009; Marchant et al., 2010; Puttonen et al., 2003; Richter-Schmidinger et al., 2011; Schultz et al., 2008; Wright et al., 2003; Yu et al., 2000). The  $\epsilon 2$  allele has been associated with reduced cognitive decline among healthy older persons (Farrer et al., 1997; Shinohara et al., 2016), reduced clinical and pathological progression in AD (Serrano-Pozo et al., 2015), and increased longevity and survival among older adults (Corder et al., 1996). It is therefore considered a protective factor against AD. The presence of both  $\epsilon 2$  and  $\epsilon 4$  alleles may have either opposing influences or synergistic effects in young age, depending on the role of the  $\epsilon 4$  allele on cognition in young age. Thus, differential inclusion of  $\epsilon 2$ - $\epsilon 4$  heterozygotes may produce variability in findings across studies.

A final source of variability between studies relates to the specific neuropsychological tests and cognitive domains under investigation. One possibility is that the  $\epsilon 4$  allele confers benefits in some domains of cognition but not in others due to a differential influence of the allele on underlying neural systems. Han and Bondi (2008) suggest that benefits on cognitive tasks in young  $\epsilon 4$  carriers may be mediated by increased recruitment of frontal-executive neural networks. This is supported by imaging work implicating the frontal-executive system as a focus of compensatory recruitment in healthy older  $\epsilon 4$  carriers (Bondi et al., 2005; Han and Bondi, 2008; Kukulja et al., 2010; Seidenberg et al., 2009; Tuminello and Han, 2011; Wierenga et al., 2010) and studies that provide evidence for increased recruitment of frontal systems in young  $\epsilon 4$  carriers (Filbey et al., 2010, 2006). However, findings regarding frontal involvement in young and older  $\epsilon 4$  carriers are mixed (Trachtenberg et al., 2012; Tuminello and Han, 2011). For example, some studies of young  $\epsilon 4$  carriers do not support increased frontal system recruitment in young  $\epsilon 4$  carriers, instead finding evidence for increased recruitment of task-related regions (e.g., Dennis et al., 2010; Filippini et al., 2009; Tuminello and Han, 2011 for review). To the degree that the  $\epsilon 4$  allele results in increased recruitment of neural networks underlying specific cognitive functions, performance differences between  $\epsilon 4$  and non- $\epsilon 4$  persons may arise for some cognitive domains but not others.

A recent meta-analysis by Ihle and colleagues (Ihle et al., 2012) sought to integrate findings across studies reporting on associations between APOE  $\epsilon 4$  and cognition in younger persons. The authors did not find an association between presence of the  $\epsilon 4$  allele and

cognition in persons between the ages of 5 and 35. Based on a potential association between the  $\epsilon 4$  allele and frontal-executive networks (Han and Bondi, 2008), the authors also conducted post-hoc analyses to investigate whether tasks requiring increased executive demands would moderate the association between possession of the  $\epsilon 4$  allele and performance on cognitive measures. Findings were non-significant. The authors conclude that the antagonistic pleiotropy hypothesis of APOE  $\epsilon 4$  should be treated with caution.

Findings of Ihle et al. (2012) are informative and important. However, for several reasons, an updated meta-analysis is needed. Most relevant is the fact that new studies have been published since the 2012 meta-analysis. Additionally, although Ihle et al. investigated moderating effects of executive demands, the authors did not specifically examine other cognitive domains which may reveal associations with the  $\epsilon 4$  allele and acknowledge this as a limiting factor in their study. Finally, Ihle and colleagues also analyzed studies that included  $\epsilon 2$ - $\epsilon 4$  heterozygote participants, which can introduce confounds due to well-established protective factors of the  $\epsilon 2$  allele. Thus, the aim of the present meta-analysis is to update and extend findings of Ihle et al. with these considerations in mind. To this end, we embarked on a systematic literature review of studies that report associations between cognition and APOE in younger persons (infancy to age 40) and quantitatively integrated these findings using meta-analytical techniques across seven cognitive domains.

## 2. Methods

### 2.1. Literature search

This meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Liberati et al., 2009; Moher et al., 2009). In accordance with PRISMA guidelines, the project was registered with PROSPERO, the international prospective register of systematic reviews (registration number: CRD42017079478). The literature search was conducted on October 13, 2017 with no imposed date restriction. The search term “(APOE or Apolipoprotein  $\epsilon$ ) and (cognition or cognitive function or neuropsychology or neuropsychological tests)” was applied to PubMed and PsychINFO databases, with APOE used as a common abbreviation for apolipoprotein E. Age limits were selected in the search engine menu in order to restrict results to the age range of interest. For PubMed, child (birth to 18) and adult, ages 19–44, were selected. For PsychInfo, we selected 30 s, young adulthood, adolescence, childhood, school age, preschool, infancy, and neonatal.

### 2.2. Inclusion/Exclusion criteria

Inclusion criteria were as follows: 1) human subject research, 2) participant age range of less than or equal to 40 years of age, 3) non-clinical samples (i.e., not meeting criteria for a medical or mental health condition that could impair cognition), 4) report of at least one neuropsychological or cognitive outcome measure, and 5) report of cognitive outcomes stratified by  $\epsilon 4$  and non- $\epsilon 4$  groups. We excluded studies that 1) focused on animal research, 2) focused on another topic (e.g., brain injury, cancer), 3) were duplicate studies, 4) did not report data separately for APOE  $\epsilon 4$  and non- $\epsilon 4$  groups, 5) included  $\epsilon 2$ - $\epsilon 4$  heterozygotes, 6) were not empirical, peer-reviewed research articles (e.g., dissertation, books, abstract only, conference presentations, case studies) or 6) lacked cognitive outcomes. The decision to

exclude APOE- $\epsilon$ 2 carriers from the  $\epsilon$ 4 group was made due to the potential confound of protective effects that are conferred by the allele (Farrer et al., 1997).

### 2.3. Data extraction and risk of bias

Two authors (GHW and SDH) independently reviewed all individual titles and abstracts of citations yielded from the search. Disagreements that arose for citations were discussed until an agreed-upon decision was reached. Full-text articles were downloaded and reviewed whenever there was a question regarding one of the selection criteria. Risk of bias was assessed at the study level for selective reporting, incomplete outcome data, quality of experimental design (e.g., inadequate sample size per genotype group, demographic considerations, IRB approval for research procedures), and undue influence of funding sources. Studies judged to indicate a potential risk of bias were excluded from review. Each article was reviewed by GHW and SDH for potential risk of bias with disagreements settled through discussion.

### 2.4. Data analysis

Outcomes in the present study were neuropsychological or cognitive test scores (e.g., experimental designs, fMRI tasks) stratified by genotype group ( $\epsilon$ 4 vs. non- $\epsilon$ 4). The  $\epsilon$ 4 group included homozygotes of the  $\epsilon$ 4 allele as well as more commonly occurring  $\epsilon$ 3/ $\epsilon$ 4 heterozygotes. The non- $\epsilon$ 4 group consisted of  $\epsilon$ 3 homozygotes,  $\epsilon$ 2 homozygotes, and  $\epsilon$ 2/3 heterozygotes. Tests were grouped into the following seven categories to assess for any specific effects by domain: achievement/intelligence, attention/working memory, executive functioning, language, memory, processing speed, and visuospatial abilities. To examine whether  $\epsilon$ 4 and non- $\epsilon$ 4 groups differ across each of the seven domains, Hedges'  $g$  (Hedges, 1981) were calculated with random effects models, which assume that the true effect size might differ from study to study. Thus, results are weighted based on study sample size, allowing inferences to be extended beyond the studies included in the meta-analysis (Hedges and Vevea, 1998). Statistical analyses were conducted using Comprehensive Meta Analysis (CMA) software, version 3.3.070 (Biostat, Englewood, NJ). Forest plots were visualized using CMA, and results were deemed significant at an alpha of  $p < .05$ . Follow-up analyses were conducted excluding studies that included sub-groups of  $\epsilon$ 4 and non- $\epsilon$ 4 carriers with an additional risk factor for AD or cognitive impairment (e.g., positive family history of AD). As a quality control measure, if fewer than five studies were available for a particular analysis, the analysis was not conducted due to lack of adequate data. This was not the case for any of the analyses.

Heterogeneity, which refers to the variability or diversity of studies included in a systematic review, can impact the robustness and generalizability of the results (Higgins et al., 2003; Thompson, 1994). Heterogeneity was considered via statistical calculation of  $Q$ ,  $\tau$ ,  $\tau^2$ , and  $I^2$ .  $Q$  provides a measure of absolute heterogeneity of effects with a corresponding  $p$ -value (Cochran, 1954).  $\tau$  and  $\tau^2$  provide measures of the standard deviation and variance of true effects respectively (Borenstein et al., 2010), and provide a basis for comparison across studies.  $I^2$  refers to a ratio of true effect variance to observed error variance (Higgins et al., 2003).

Table 1 lists the measures extracted from articles that were used in the present review according to each cognitive domain. Per meta-analysis convention, if more than one measure was reported in a single study for a given cognitive domain, outcomes were pooled and the mean effect size was used. If a study further subdivided  $\epsilon 4$  and non- $\epsilon 4$  participants into subgroups based on a common factor (e.g., sex), each subgroup was considered to be a separate data point.

### 3. Results

#### 3.1. Study selection

Search of databases yielded 689 records with an additional 32 records identified through other sources (e.g., reference lists of review articles). Following removal of duplicates, 635 records were screened by reviewing titles and abstracts. Of these, 79 were removed based on the title (e.g., case study, non-English language, irrelevant topic) and 412 were removed after reading the abstract (e.g., animal study, clinical sample, out of age range, review paper, dissertation, book). Thus, 144 full-text articles were assessed for eligibility and 101 were excluded following full-text review. Most of these studies ( $n = 63$ ) were excluded for being outside of the pre-specified age range. These were studies in which the age range was unclear based on reading the abstract alone. Sixteen studies included  $\epsilon 2$  carriers in the  $\epsilon 4$  group, 13 did not report cognitive outcomes, and nine focused on APOE genotype in the context of a disease state or health condition (e.g., cancer, stroke, brain injury, cardiovascular disease). After these exclusions, 43 articles remained in the qualitative synthesis. Further assessment of records revealed three studies that met criteria for risk of bias, two due to small sample sizes per genotype group and one due to methodological concerns. Three studies were excluded because they reported identical data as other studies that were included in the quantitative synthesis. In these cases, the studies that provided more cognitive outcome data were selected. Ten articles reported data in a different format than the format necessary for the quantitative synthesis or were missing values (means and/or standard deviations) for relevant cognitive measures. In an attempt to include these studies, emails were sent to corresponding authors requesting data. Two authors responded by the date of preparation of this manuscript and were included in the final quantitative synthesis. In sum, 29 studies remained in the quantitative meta-analysis. Five of the 29 included studies subdivided genotype groups by other factors (e.g., sex) yielding a total of 34 data points to be included in the quantitative synthesis. Fig. 1 presents the flowchart for determining study inclusion into the meta-analysis.

#### 3.2. APOE $\epsilon 4$ vs. APOE non- $\epsilon 4$

Demographic data per study are presented in Table 2. Comparing performance of  $\epsilon 4$  and non- $\epsilon 4$  persons on measures across all domains combined revealed a summary effect size that did not significantly differ from zero ( $p = .98$ ). Examining each of the seven domains separately also revealed no differences between groups for the domains of achievement/intelligence, attention/working memory, language, memory, processing speed, and visuospatial abilities (all  $p$ s  $> 0.22$ ). With regard to executive functioning, a marginal trend arose in which  $\epsilon 4$  persons scored higher than non- $\epsilon 4$  persons (13 studies,  $H_g = .251$ ,  $SE_g = .152$ , 95% CI =  $-0.05$ – $0.56$ ,  $p = .098$ ). Heterogeneity was found to be in the high range for



executive functioning ( $Q = 48.68$ ,  $p < .001$ ,  $I^2 = 75.35$ ,  $\text{Tau} = 0.45$ ,  $\text{Tau}^2 = 0.20$ ). Fig. 2 presents the forest plot for the domain of executive functioning. Forest plots for all other domains can be visualized in Supplementary Materials (Figs. S1–S7).

### 3.3. Follow-up analysis

To investigate whether inclusion of “high-risk” groups would impact study findings, we re-analyzed data excluding the positive family history sub-sample from Bloss et al. (2008), the high prenatal mercury exposure sub-sample from Ng et al. (2013), and data from Green et al. (2014) who investigated differences between  $\epsilon 4$  and non- $\epsilon 4$  carriers who also had the CLU-C genotype. This was relevant for the combined domains analysis and for analyses of achievement/intelligence, executive functioning, language, processing speed, and visuospatial abilities. Findings remain non-significant across all domains combined, and the domains of achievement/intelligence, language, processing speed, and visuospatial abilities after excluding data points reflecting high-risk sub-samples. For executive functioning, only the Green et al. (2014) study was removed. In doing so, the summary effect is no longer marginal (12 studies,  $H_g = .241$ ,  $SE_g = .162$ , 95% CI =  $-0.08$ – $0.56$ ,  $p = 0.14$ ). Heterogeneity remains high ( $Q = 47.86$ ,  $p < .001$ ,  $I^2 = 77.02$ ,  $\text{Tau} = 0.47$ ,  $\text{Tau}^2 = 0.22$ ).

## 4. Discussion

This meta-analysis examined associations between cognition and presence of the APOE  $\epsilon 4$  allele in younger persons. Findings were nonsignificant, suggesting that in children and young adults,  $\epsilon 4$  and non- $\epsilon 4$  carriers perform similarly on cognitive tests. Findings from the present meta-analysis converge with a previous meta-analysis conducted by Ihle et al. (2012), providing further support against the antagonistic pleiotropic hypothesis of the  $\epsilon 4$  allele as originally proposed by Han and Bondi (2008).

Examining cognitive differences between  $\epsilon 4$  and non- $\epsilon 4$  persons separately across each of seven cognitive domains allowed for interrogation of associations between APOE  $\epsilon 4$  and specific areas of functioning. Based on fMRI research suggesting functional differences in executive-frontal neural networks in young and older  $\epsilon 4$  carriers (for review see Han and Bondi, 2008; Tuminello and Han, 2011), we postulated whether specific cognitive domains would show differences above others. Findings were non-significant across all domains assessed including achievement/intelligence, attention/working memory, language, memory, executive functioning, processing speed, and visuospatial abilities. In regard to executive functioning, a non-significant marginal difference arose such that  $\epsilon 4$  carriers outperformed non- $\epsilon 4$  carriers on measures of executive functioning. This finding diverges from Ihle et al. (2012), who approached the question differently. In their meta-analysis, Ihle et al. subdivided tasks into those involving high executive demands and those involving low executive demands and did not find evidence of differences between  $\epsilon 4$  and non- $\epsilon 4$  carriers on tasks with high executive demands.

Executive functioning reflects a range of abilities (e.g., set-shifting, inhibition, decision making) that are assessed with a variety of different cognitive tests, but all are believed to be frontally mediated. Han and Bondi (2008) speculated as part of their antagonistic pleiotropy hypothesis that “frontal-executive cognitive processes might mediate the APOE  $\epsilon 4$



advantage in youth and the compensatory mechanisms invoked later in life.” The marginal finding of better scores on measures of executive functioning in young  $\epsilon 4$  carriers relative to non- $\epsilon 4$  carriers aligns well with this aspect of the antagonistic pleiotropy hypothesis initially proposed by Han & Bondi. However, for several reasons, we now caution against interpreting this marginal finding as support for the antagonistic pleiotropy hypothesis. First, evidence for associations between the  $\epsilon 4$  allele and frontal-executive neural networks is inconclusive. While a small number of fMRI studies support increased recruitment of frontal executive networks in young  $\epsilon 4$  carriers (Filbey et al., 2010, 2006), a larger group of studies instead report increased neural recruitment of regions specific to the administered task (Dennis et al., 2010; Filippini et al., 2009; Tuminello and Han, 2011). In their literature review and reassessment of the antagonistic pleiotropy hypothesis, Tuminello and Han (2011) suggest that the preponderance of studies supporting increased frontal recruitment in younger  $\epsilon 4$  carriers is likely due to utilization of frontally mediated tasks (e.g., Filbey et al., 2010 used a working memory task). The authors propose a revision of the antagonistic pleiotropy hypothesis to account for these findings, suggesting that compensatory neural recruitment in young  $\epsilon 4$  carriers occurs in task-related regions rather than frontally-mediated regions. Thus, our finding of better performance in the domain of executive functioning but not in other cognitive domains does not seem to be supported by fMRI studies or the most recent revision of the antagonistic pleiotropy hypothesis (Tuminello and Han, 2011).

A second reason to caution against over-interpretation of this marginal finding relates to the high heterogeneity statistics of this analysis. High heterogeneity in meta-analyses suggests that the variability between studies is not due only to chance but also to the measurement of different effects across studies (Higgins et al., 2003; Thompson, 1994). This limits the generalizability of findings of a meta-analysis (Higgins et al., 2003; Thompson, 1994), although some have suggested that certain heterogeneity estimates are less reliable with smaller sample sizes of studies (Huedo-Medina et al., 2006; Ioannidis et al., 2007; von Hippel, 2015). One potential reason for high heterogeneity in this domain relates to the broad range of abilities that fall under executive functioning and the difficulty of isolating such abilities due to lower order processes that are also necessary for completing executive tasks (i.e., task impurity; Miyake and Friedman, 2012). Nevertheless, in light of high heterogeneity and a marginal trend towards significance, the executive functioning finding reported in the present meta-analysis should be interpreted with extreme caution and necessitates replication, ideally with a larger sample of studies, in order to clarify whether this finding may represent a true effect. A possibility that remains to be addressed is the notion that the  $\epsilon 4$  effect is specific to one component of executive functioning. Future studies may consider further subdividing executive tasks into component processes to investigate this possibility.

Overall, the present findings do not support an antagonistic pleiotropic effect of the  $\epsilon 4$  allele as it relates to cognition in younger age ranges. One possibility that the present study cannot rule out is a differential effect of the  $\epsilon 4$  allele on cognition later in the lifespan. Exaggerated cognitive decline in older  $\epsilon 4$  carriers compared to non- $\epsilon 4$  carriers is well-established in the literature (see Tuminello and Han, 2011 for review). However, one study reported higher cognitive performances in oldest-old  $\epsilon 4$  carriers compared to oldest-old non- $\epsilon 4$  carriers (Carrion-Baralt et al., 2009). Additionally, other studies do not find exaggerated cognitive

decline in  $\epsilon 4$  compared to non- $\epsilon 4$  carriers when examining oldest-old persons as is typically found in young-old carriers (Juva et al., 2000; Kozauer et al., 2008; Welsh-Bohmer et al., 2009), suggesting that the effect of  $\epsilon 4$  on cognition is age specific. As a result of such findings, some have suggested that the  $\epsilon 4$  allele may exhibit antagonistic pleiotropy effects particularly in young-old and old-old age (Carrion-Baralt et al., 2009; Tuminello and Han, 2011), with a negative impact on cognition in young-old individuals and a positive impact in the oldest old. Future research can examine this in greater detail.

Visual examination of forest plots highlights the variable effect sizes found across studies within each cognitive domain assessed, and estimated heterogeneity parameters confirm this observation (see Supplemental Materials). Qualitatively, studies differed across many factors and this may have contributed to the high level of inconsistency between studies. One source of variability between studies is the specific age range under investigation. While some studies imposed a very restrictive age range (e.g., 20–24 years old, Bunce et al., 2011, 2014; age 14, Dell'Acqua et al., 2015), others examined a much wider age range of young  $\epsilon 4$  and non- $\epsilon 4$  carriers (e.g., 20–40 years old, Suri et al., 2015; 18–30 years old, Kunz et al., 2015). Tuminello and Han (2011) suggest that pleiotropic effects of the  $\epsilon 4$  allele in younger persons may be restricted to a narrow age range, and thus assessing associations across a wide range of ages may contribute to inconsistencies between studies. To further explore this possibility, we examined the impact of age on differences between  $\epsilon 4$  and non- $\epsilon 4$  groups for all measures combined. We did this by calculating a weighted average of the average ages provided for  $\epsilon 4$  and non- $\epsilon 4$  groups. Five studies were excluded because they provided age ranges, rather than averages, in their sample characteristics. Age did not explain a significant portion of the variance in cognitive differences between  $\epsilon 4$  and non- $\epsilon 4$  carriers ( $p = 0.99$ ), arguing against pleiotropic effects specific to narrower age ranges. Due to small numbers of studies within each cognitive domain, we could not investigate age as a moderator for each cognitive domain separately due to the propensity of Type 1 errors in meta-regression analyses (Higgins and Thompson, 2004).

A second source of variability relates to the specific allele composition of  $\epsilon 4$  and non- $\epsilon 4$  carriers assessed. Some studies included  $\epsilon 2$  hetero- or homozygotes in their non- $\epsilon 4$  group (e.g., (Alexopoulos et al., 2011; Bloss et al., 2008; Dennis et al., 2010) while others only included  $\epsilon 3$  homozygotes (e.g., Bloss et al., 2010; Matura et al., 2016, 2014; Wierenga et al., 2013). Although we excluded studies that included  $\epsilon 2$ - $\epsilon 4$  participants, we opted not to exclude studies that included  $\epsilon 2$  carriers in their non- $\epsilon 4$  group due to the already small number of studies meeting criteria for inclusion in the meta-analysis. Differences between studies with regard to the non- $\epsilon 4$  groups may contribute to variability in findings across studies, especially given the protective effect on cognition associated with the  $\epsilon 2$  allele (Corder et al., 1996; Farrer et al., 1997; Serrano-Pozo et al., 2015; Shinohara et al., 2016). Relatedly, we included both  $\epsilon 3$ - $\epsilon 4$  and  $\epsilon 4$ - $\epsilon 4$  participants in the  $\epsilon 4$  group, also potentially introducing a source of variability to the findings. Examining a dose-response effect of the  $\epsilon 4$  allele was not possible due to the small number of studies under consideration in the present meta-analysis.

A final important source of variability between studies is the decision by some studies to include high-risk subgroups of  $\epsilon 4$  and non- $\epsilon 4$  carriers (e.g., family history of AD, Bloss et

al., 2008; presence of CLU-C genotype, Green et al., 2014; prenatal mercury exposure, Ng et al., 2013). Inclusion of other factors that can contribute to cognitive differences between groups makes interpretation of associations between  $\epsilon 4$  and cognition difficult (Tuminello and Han, 2011). Excluding the three studies (Bloss et al., 2008; Green et al., 2014; Ng et al., 2013) that included high-risk groups did not change the outcome of the majority of analyses. However, excluding Green et al. (2014) from the executive functioning analysis reduced the marginal effect to a null effect, further warranting cautious interpretation of this marginal finding.

High heterogeneity across studies is one limitation of this meta-analysis. Other limitations include the small number of studies meeting inclusionary criteria, highlighting the fact that studies examining the cognitive effects of the  $\epsilon 4$  allele in healthy young persons are few and far between. A second related limitation is the lack of power to fully assess for moderating variables such as age and sex. This should be a consideration for future meta-analyses that aim to examine the relationship of the  $\epsilon 4$  allele with cognition in younger persons. A final limitation is the wide age range considered in the study, ranging from toddlers to 40 year olds. This was unavoidable given the already small number of studies under consideration.

Findings from the meta-analysis largely do not support the  $\epsilon 4$  allele as a pleiotropic gene, replicating findings of an earlier report by Ihle et al. (2012). The present meta-analysis also extends findings of Ihle et al. by showing that differences between young  $\epsilon 4$  and non- $\epsilon 4$  carriers were null across all cognitive domains assessed including achievement/intelligence, attention/working memory, language, memory, processing speed, and visuospatial abilities. A marginal trend arose in which  $\epsilon 4$  carriers outperformed non- $\epsilon 4$  carriers on measures of executive functioning, but further replication is needed in light of high heterogeneity between studies and a small number of studies considered. Importantly, high variability between studies reported in the present meta-analysis highlights the need for more research in this area, particularly with greater consistency in the parameters implemented across studies.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work is supported by National Institute on Aging [grant number R01AG055430] awarded to SDH; and the Department of Family Medicine of the University of Southern California, as well as National Institute on Aging [grant numbers R21AG055034, P01AG052350, P50AG005142] and Alzheimer's Association [grant number AARG-17-532905] awarded to DAN; National Institute on Aging [K24 AG026431 and R01 AG049810] to MWB; and the Department of Psychology, University of Southern California. Authors acknowledge the Department of Family Medicine of University of Southern California for support of this work.

## References<sup>1</sup>

Acevedo SF, Piper BJ, Craytor MJ, Benice TS, Raber J, 2010 Apolipoprotein E4 and sex affect neurobehavioral performance in primary school children. *Pediatr. Res.* 67, 293–299. [PubMed: 19952867]

- Albin RL, 1993 Antagonistic pleiotropy, mutation accumulation, and human genetic disease. *Genetica* 91, 279–286. [PubMed: 8125276]
- Alexander DM, Williams LM, Gatt JM, Dobson-Stone C, Kuan SA, Todd EG, Schofield PR, Cooper NJ, Gordon E, 2007 The contribution of apolipoprotein E alleles on cognitive performance and dynamic neural activity over six decades. *Biol. Psychol.* 75, 229–238. [PubMed: 17433528]
- \*Alexopoulos P, Richter-Schmidinger T, Horn M, Maus S, Reichel M, Sidiropoulos C, Rhein C, Lewczuk P, Doerfler A, Kornhuber J, 2011 Hippocampal volume differences between healthy young apolipoprotein E epsilon2 and epsilon4 carriers. *J. Alzheimers Dis.* 26, 207–210. [PubMed: 21606569]
- \*Bloss CS, Delis DC, Salmon DP, Bondi MW, 2008 Decreased cognition in children with risk factors for Alzheimer’s disease. *Biol. Psychiatry* 64, 904–906. [PubMed: 18722591]
- \*Bloss CS, Delis DC, Salmon DP, Bondi MW, 2010 APOE genotype is associated with left-handedness and visuospatial skills in children. *Neurobiol. Aging* 31, 787–795. [PubMed: 18606479]
- Bondi MW, Salmon DP, Monsch AU, Galasko D, Butters N, Klauber MR, Thal LJ, Saitoh T, 1995 Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. *Neurology* 45, 2203–2206. [PubMed: 8848194]
- Bondi MW, Houston WS, Eylert LT, Brown GG, 2005 fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. *Neurology* 64, 501–508. [PubMed: 15699382]
- Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW, 2000 Patterns of brain activation in people at risk for Alzheimer’s disease. *N. Engl. J. Med.* 343 450–456. [PubMed: 10944562]
- Borenstein M, Hedges LV, Higgins JP, Rothstein HR, 2010 A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res. Synth. Methods* 1, 97–111. [PubMed: 26061376]
- \*Bunce D, Anstey KJ, Burns R, Christensen H, Eastaer S, 2011 Does possession of apolipoprotein E varepsilon4 benefit cognitive function in healthy young adults? *Neuropsychologia* 49, 1693–1697. [PubMed: 21396385]
- \*Bunce D, Bielak AA, Anstey KJ, Cherbuin N, Batterham PJ, Eastaer S, 2014 APOE genotype and cognitive change in young, middle-aged, and older adults living in the community. *J. Gerontol. A Biol. Sci. Med. Sci.* 69, 379–386. [PubMed: 23902936]
- \*Calderon-Garciduenas L, Mora-Tiscareno A, Franco-Lira M, Zhu H, Lu Z, Solorio E, Torres-Jardon R, D’Angiulli A, 2015 Decreases in short term memory, IQ, and altered brain metabolic ratios in urban apolipoprotein epsilon4 children exposed to air pollution. *J. Alzheimers Dis.* 45, 757–770. [PubMed: 25633678]
- \*Calderon-Garciduenas L, Jewells V, Galaz-Montoya C, van Zundert B, Perez-Calatayud A, Ascencio-Ferrel E, Valencia-Salazar G, Sandoval-Cano M, Carlos E, Solorio E, Acuna-Ayala H, Torres-Jardon R, D’Angiulli A, 2016 Interactive and additive influences of Gender, BMI and Apolipoprotein 4 on cognition in children chronically exposed to high concentrations of PM2.5 and ozone. APOE 4 females are at highest risk in Mexico City. *Environ Res* 150, 411–422. [PubMed: 27376929]
- Carrion-Baralt JR, Melendez-Cabrero J, Schnaider Beerli M, Sano M, Silverman JM, 2009 The neuropsychological performance of nondemented Puerto Rican nonagenarians. *Dement. Geriatr. Cogn. Disord.* 27, 353–360. [PubMed: 19293568]
- Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, Alexander GG, 2004 Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. *Neurology* 62, 1990–1995. [PubMed: 15184602]
- Cochran WG, 1954 The combination of estimates from different experiments. *Biometrics* 10, 101–129.
- Corder EH, Lannfelt L, Viitanen M, Corder LS, Manton KG, Winblad B, Basun H, 1996 Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition. *Arch. Neurol.* 53, 418–422. [PubMed: 8624216]
- Deary IJ, Whalley LJ, Clair DS, Breen G, Leaper S, Lemmon H, Hayward C, Starr JM, 2003 The influence of the e4 allele of the apolipoprotein E gene on childhood IQ, nonverbal reasoning in old age, and lifetime cognitive change. *Intelligence* 31, 85–92.

---

<sup>1</sup>\*Studies included in the meta-analysis are denoted with an asterisk.

- \*Dell'Acqua F, Khan W, Gottlieb N, Giampietro V, Ginestet C, Bouls D, Newhouse S, Dobson R, Banaschewski T, Barker GJ, Bokde AL, Buchel C, Conrod P, Flor H, Frouin V, Garavan H, Gowland P, Heinz A, Lemaitre H, Nees F, Paus T, Pausova Z, Rietschel M, Smolka MN, Strohle A, Gallinat J, Westman E, Schumann G, Lovestone S, Simmons A, consortium, I, 2015 Tract based spatial statistic reveals no differences in white matter microstructural organization between carriers and non-carriers of the APOE varepsilon4 and varepsilon2 alleles in young healthy adolescents. *J. Alzheimers Dis.* 47, 977–984. [PubMed: 26401776]
- Den Heijer T, Oudkerk M, Launer L, Van Duijn C, Hofman A, Breteler M, 2002 Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. *Neurology* 59, 746–748. [PubMed: 12221169]
- \*Dennis NA, Browndyke JN, Stokes J, Need A, Burke JR, Welsh-Bohmer KA, Cabeza R, 2010 Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. *Alzheimers Dement.* 6, 303–311. [PubMed: 19744893]
- \*Dowell NG, Ruest T, Evans SL, King SL, Tabet N, Tofts PS, Rusted JM, 2013 MRI of carriers of the apolipoprotein E e4 allele-evidence for structural differences in normal-appearing brain tissue in e4+ relative to e4– young adults. *NMR Biomed.* 26, 674–682. [PubMed: 23364916]
- \*Evans S, Dowell NG, Tabet N, Tofts PS, King SL, Rusted JM, 2014 Cognitive and neural signatures of the APOE E4 allele in mid-aged adults. *Neurobiol. Aging* 35, 1615–1623. [PubMed: 24582638]
- Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, 1997 Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. *JAMA* 278, 1349–1356. [PubMed: 9343467]
- Filbey FM, Slack KJ, Sunderland TP, Cohen RM, 2006 Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEepsilon4 in young healthy adults. *Neuroreport* 17, 1585–1590. [PubMed: 17001273]
- Filbey FM, Chen G, Sunderland T, Cohen RM, 2010 Failing compensatory mechanisms during working memory in older apolipoprotein E-epsilon4 healthy adults. *Brain Imaging Behav.* 4, 177–188. [PubMed: 20502990]
- \*Filippini N, Macintosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE, 2009 Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. *Proc. Natl. Acad. Sci. U. S. A.* 106, 7209–7214. [PubMed: 19357304]
- \*Green AE, Gray JR, Deyoung CG, Mhyre TR, Padilla R, Dibattista AM, William Rebeck G, 2014 A combined effect of two Alzheimer's risk genes on medial temporal activity during executive attention in young adults. *Neuropsychologia* 56, 1–8. [PubMed: 24388797]
- Han SD, Bondi MW, 2008 Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. *Alzheimers Dement.* 4, 251–254. [PubMed: 18631975]
- Hedges LV, 1981 Distribution theory for Glass's estimator of effect size and related estimators. *J. Educ. Stat.* 6, 107–128.
- Hedges LV, Vevea JL, 1998 Fixed-and random-effects models in meta-analysis. *Psychol. Methods* 3, 486.
- Higgins JP, Thompson SG, 2004 Controlling the risk of spurious findings from meta-regression. *Stat. Med.* 23, 1663–1682. [PubMed: 15160401]
- Higgins JP, Thompson SG, Deeks JJ, Altman DG, 2003 Measuring inconsistency in meta-analyses. *BMJ* 327, 557–560. [PubMed: 12958120]
- Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J, 2006 Assessing heterogeneity in meta-analysis: Q statistic or I2 index? *Psychol. Methods* 11, 193–206. [PubMed: 16784338]
- Ihle A, Bunce D, Kliegel M, 2012 APOE epsilon4 and cognitive function in early life: a meta-analysis. *Neuropsychology* 26, 267–277. [PubMed: 22329498]
- Ioannidis JP, Patsopoulos NA, Evangelou E, 2007 Uncertainty in heterogeneity estimates in meta-analyses. *BMJ* 335, 914–916. [PubMed: 17974687]
- Jochemsen HM, Muller M, van der Graaf Y, Geerlings MI, 2012 APOE epsilon4 differentially influences change in memory performance depending on age. The SMART-MR study. *Neurobiol. Aging* 33 (832), e815–822.




- \*Jorm AF, Mather KA, Butterworth P, Anstey KJ, Christensen H, Eastaer S, 2007 APOE genotype and cognitive functioning in a large age-stratified population sample. *Neuropsychology* 21, 1–8. [PubMed: 17201525]
- Juva K, Verkkoniemi A, Viramo P, Polvikoski T, Kainulainen K, Kontula K, Sulkava R, 2000 APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. *Neurology* 54, 412–415. [PubMed: 10668704]
- Kozauer NA, Mielke MM, Chan GK, Rebok GW, Lyketsos CG, 2008 Apolipoprotein E genotype and lifetime cognitive decline. *Int. Psychogeriatr.* 20, 109–123. [PubMed: 17711604]
- Kukulja J, Thiel CM, Eggermann T, Zerres K, Fink GR, 2010 Medial temporal lobe dysfunction during encoding and retrieval of episodic memory in non-demented APOE epsilon4 carriers. *Neuroscience* 168, 487–497. [PubMed: 20350587]
- \*Kunz L, Schroder TN, Lee H, Montag C, Lachmann B, Sariyska R, Reuter M, Stirnberg R, Stocker T, Messing-Floeter PC, Fell J, Doeller CF, Axmacher N, 2015 Reduced grid-cell-like representations in adults at genetic risk for Alzheimer’s disease. *Science* 350, 430–433. [PubMed: 26494756]
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D, 2009 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* 6, e1000100. [PubMed: 19621070]
- Luciano M, Gow AJ, Harris SE, Hayward C, Allerhand M, Starr JM, Visscher PM, Deary IJ, 2009 Cognitive ability at age 11 and 70 years, information processing speed, and APOE variation: the Lothian Birth Cohort 1936 study. *Psychol. Aging* 24, 129–138. [PubMed: 19290744]
- Marchant NL, King SL, Tabet N, Rusted JM, 2010 Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers. *Neuropsychopharmacology* 35, 1090–1096. [PubMed: 20072115]
- \*Matura S, Prvulovic D, Jurcoane A, Hartmann D, Miller J, Scheibe M, O’Dwyer L, Oertel-Knochel V, Knochel C, Reinke B, Karakaya T, Fusser F, Pantel J, 2014 Differential effects of the ApoE4 genotype on brain structure and function. *Neuroimage* 89, 81–91. [PubMed: 24296331]
- \*Matura S, Prvulovic D, Hartmann D, Scheibe M, Sepanski B, Butz M, Oertel-Knochel V, Knochel C, Karakaya T, Fusser F, Hattingen E, Pantel J, 2016 Age-related effects of the apolipoprotein E gene on brain function. *J. Alzheimers Dis.* 52, 317–331. [PubMed: 27003211]
- Miyake A, Friedman NP, 2012 The nature and organization of individual differences in executive functions: four general conclusions. *Curr. Dir. Psychol. Sci.* 21, 8–14. [PubMed: 22773897]
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group P, 2009 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 6, e1000097. [PubMed: 19621072]
- \*Mondadori CR, de Quervain DJ, Buchmann A, Mustovic H, Wollmer MA, Schmidt CF, Boesiger P, Hock C, Nitsch RM, Papassotiropoulos A, Henke K, 2007 Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. *Cereb. Cortex* 17, 1934–1947. [PubMed: 17077159]
- Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA, 2010 APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann. Neurol.* 67, 122–131. [PubMed: 20186853]
- Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K, 1991 Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. *Brain Res.* 541, 163–166. [PubMed: 2029618]
- \*Ng S, Lin CC, Hwang YH, Hsieh WS, Liao HF, Chen PC, 2013 Mercury, APOE, and children’s neurodevelopment. *Neurotoxicology* 37, 85–92. [PubMed: 23603214]
- \*Nichols LM, Masdeu JC, Mattay VS, Kohn P, Emery M, Sambataro F, Kolachana B, Elvevag B, Kippenhan S, Weinberger DR, Berman KF, 2012 Interactive effect of apolipoprotein e genotype and age on hippocampal activation during memory processing in healthy adults. *Arch. Gen. Psychiatry* 69, 804–813. [PubMed: 22868934]
- \*O’Dwyer L, Lambertson F, Matura S, Scheibe M, Miller J, Rujescu D, Prvulovic D, Hampel H, 2012 White matter differences between healthy young ApoE4 carriers and non-carriers identified with tractography and support vector machines. *PLoS One* 7, e36024. [PubMed: 22558310]

- Puttonen S, Elovainio M, Kivimaki M, Lehtimaki T, Keltikangas-Jarvinen L, 2003 The combined effects of apolipoprotein E polymorphism and low-density lipoprotein cholesterol on cognitive performance in young adults. *Neuropsychobiology* 48, 35–40. [PubMed: 12886039]
- \*Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J, 2004 Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. *Proc. Natl. Acad. Sci. U. S. A.* 101, 284–289. [PubMed: 14688411]
- Richter-Schmidinger T, Alexopoulos P, Horn M, Maus S, Reichel M, Rhein C, Lewczuk P, Sidiropoulos C, Kneib T, Perneczky R, Doerfler A, Kornhuber J, 2011 Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. *J. Neural. Transm. (Vienna)* 118, 249–257. [PubMed: 21190051]
- \*Ruiz JR, Castillo R, Labayen I, Moreno LA, Fuentes MG, Lamuno DG, Alvarez Granda JL, Lucia A, Ortega FB, Group AS, 2010 Individual and combined effects of ApoE and MTHFR 677C/T polymorphisms on cognitive performance in Spanish adolescents: the AVENA study. *J. Pediatr.* 156, 978–984 e971. [PubMed: 20223480]
- Rusted JM, Evans SL, King SL, Dowell N, Tabet N, Tofts PS, 2013 APOE e4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures. *Neuroimage* 65, 364–373. [PubMed: 23063453]
- Salvato G, 2015 Does apolipoprotein E genotype influence cognition in middle-aged individuals? *Curr. Opin. Neurol.* 28, 612–617. [PubMed: 26402402]
- Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al., 1993 Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* 43, 1467–1472. [PubMed: 8350998]
- Scarmeas N, Stern Y, 2006 Imaging studies and APOE genotype in persons at risk for Alzheimer's disease. *Curr. Psychiatry Rep.* 8, 11–17. [PubMed: 16513038]
- Schultz MR, Lyons MJ, Franz CE, Grant MD, Boake C, Jacobson KC, Xian H, Schellenberg GD, Eisen SA, Kremen WS, 2008 Apolipoprotein E genotype and memory in the sixth decade of life. *Neurology* 70, 1771–1777. [PubMed: 18235080]
- Seidenberg M, Guidotti L, Nielson KA, Woodard JL, Durgerian S, Antuono P, Zhang Q, Rao SM, 2009 Semantic memory activation in individuals at risk for developing Alzheimer disease. *Neurology* 73, 612–620. [PubMed: 19704080]
- Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT, 2015 APOEepsilon2 is associated with milder clinical and pathological Alzheimer disease. *Ann. Neurol.* 77, 917–929. [PubMed: 25623662]
- \*Shaw P, Lerch JP, Pruessner JC, Taylor KN, Rose AB, Greenstein D, Clasen L, Evans A, Rapoport JL, Giedd JN, 2007 Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. *Lancet Neurol.* 6, 494–500. [PubMed: 17509484]
- Shinohara M, Kanekiyo T, Yang L, Linthicum D, Shinohara M, Fu Y, Price L, Frisch-Daiello JL, Han X, Fryer JD, Bu G, 2016 APOE2 eases cognitive decline during Aging: clinical and preclinical evaluations. *Ann. Neurol.*
- \*Sinclair LI, Button KS, Munafò MR, Day IN, Lewis G, 2015 Possible association of APOE genotype with working memory in young adults. *PLoS One* 10, e0135894. [PubMed: 26287823]
- Small BJ, Rosnick CB, Fratiglioni L, Backman L, 2004 Apolipoprotein E and cognitive performance: a meta-analysis. *Psychol. Aging* 19, 592–600. [PubMed: 15584785]
- Soininen H, Partanen K, Pitkänen A, Hallikainen M, Hänninen T, Helisalmi S, Mannermaa A, Ryyänen M, Koiuisto K, Riekkinen P, 1995 Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ε4 allele. *Neurology* 45, 391–392. [PubMed: 7854548]
- \*Stening E, Persson J, Eriksson E, Wahlund LO, Zetterberg H, Soderlund H, 2016 Apolipoprotein E 4 is positively related to spatial performance but unrelated to hippocampal volume in healthy young adults. *Behav. Brain Res.* 299, 11–18. [PubMed: 26581118]
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD, 1993 Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4




- allele in late-onset familial Alzheimer disease. *Proc. Natl. Acad. Sci. U. S. A.* 90, 1977–1981. [PubMed: 8446617]
- \*Suri S, Mackay CE, Kelly ME, Germuska M, Tunbridge EM, Frisoni GB, Matthews PM, Ebmeier KP, Bulte DP, Filippini N, 2015 Reduced cerebrovascular reactivity in young adults carrying the APOE epsilon4 allele. *Alzheimers Dement.* 11, 648–657 e641. [PubMed: 25160043]
- Thompson SG, 1994 Why sources of heterogeneity in meta-analysis should be investigated. *BMJ* 309, 1351–1355. [PubMed: 7866085]
- Trachtenberg AJ, Filippini N, Mackay CE, 2012 The effects of APOE-epsilon4 on the BOLD response. *Neurobiol. Aging* 33, 323–334. [PubMed: 20409610]
- Tuminello ER, Han SD, 2011 The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. *Int. J. Alzheimers Dis.* 2011, 726197. [PubMed: 21423560]
- von Hippel PT, 2015 The heterogeneity statistic I<sup>2</sup> can be biased in small meta-analyses. *BMC Med. Res. Methodol.* 15, 35. [PubMed: 25880989]
- Welsh-Bohmer KA, Ostbye T, Sanders L, Pieper CF, Hayden KM, Tschanz JT, Norton MC, Cache County Study G, 2009 Neuropsychological performance in advanced age: influences of demographic factors and Apolipoprotein E: findings from the Cache County Memory Study. *Clin. Neuropsychol.* 23, 77–99. [PubMed: 18609337]
- Wierenga CE, Stricker NH, McCauley A, Simmons A, Jak AJ, Chang YL, Delano-Wood L, Bangen KJ, Salmon DP, Bondi MW, 2010 Increased functional brain response during word retrieval in cognitively intact older adults at genetic risk for Alzheimer’s disease. *Neuroimage* 51, 1222–1233. [PubMed: 20298792]
- \*Wierenga CE, Clark LR, Dev SI, Shin DD, Jurick SM, Rissman RA, Liu TT, Bondi MW, 2013 Interaction of age and APOE genotype on cerebral blood flow at rest. *J. Alzheimers Dis.* 34, 921–935. [PubMed: 23302659]
- Williams GC, 2001 Pleiotropy, Natural Selection, and the Evolution of Senescence. *Science’s SAGE KE* 2001, 13.
- Wright RO, Hu H, Silverman EK, Tsaih SW, Schwartz J, Bellinger D, Palazuelos E, Weiss ST, Hernandez-Avila M, 2003 Apolipoprotein E genotype predicts 24-month bayley scales infant development score. *Pediatr. Res.* 54, 819–825. [PubMed: 12930912]
- Yu YW, Lin CH, Chen SP, Hong CJ, Tsai SJ, 2000 Intelligence and event-related potentials for young female human volunteer apolipoprotein E epsilon4 and non-epsilon4 carriers. *Neurosci. Lett.* 294, 179–181. [PubMed: 11072144]
- \*Zhang CC, Ren HY, Li ML, Wang Q, Deng W, Guo WJ, Lei W, Xiang B, Zhao LS, Ma XH, Yao YG, Li T, 2015 Apolipoprotein E gene polymorphisms associated with processing speed and executive functions in healthy Han Chinese. *Neurosci. Bull.* 31, 368–370. [PubMed: 25827315]



**Fig. 1.**  
PRISMA flow diagram.

Executive Functioning



**Fig. 2.** Forest plot for domain of executive functioning. Difference in means reflects APOE ε4 carriers minus APOE non-ε4 carriers. Rhombus midpoint is Hedges' g and the left and right points span the lower and upper limit.

**Table 1**

List of cognitive measures by domain.

Domain	Abbreviation	Test
<b>Achievement/Intelligence</b>		
	CAT-6 Language	California Achievement Test-6 - Language
	CAT-6 Math	California Achievement Test-6 - Math
	CAT-6 Reading	California Achievement Test-6 - Reading
	CAT-6 Spelling	California Achievement Test-6 - Spelling
	CDIT Global Score	Comprehensive Development Inventory for Infants and Toddlers - Global Score
	HAWIE-R IQ	Hamburg Wechsler Intelligence Scale Revised Test - Full Scale IQ
	IQ	Unknown source <sup>d</sup>
	MWTB-IQ	Mehrfachwahl Wortschatz Intelligenz Test B - IQ
	NART	National Adult Reading Test - Total Words
	SRA Numeric ability	SRA Test of Educational Ability - Spanish, Numeric Ability
	SRA Reasoning ability	SRA Test of Educational Ability - Spanish, Reasoning Ability
	SRA Verbal ability	SRA Test of Educational Ability - Spanish, Verbal Ability
	WAIS Full-Scale IQ	Wechsler Adult Intelligence Scale (unspecified edition) - Full Scale IQ
	WISC-III Full-Scale IQ	Wechsler Intelligence Scale for Children Third Edition - Full Scale IQ
	WISC-IV Perceptual Reasoning Index	Wechsler Intelligence Scale for Children Fourth Edition - Perceptual Reasoning Index
	WISC-IV Verbal Comprehension Index	Wechsler Intelligence Scale for Children Fourth Edition - Verbal Comprehension Index
	WISC-R Performance IQ	Wechsler Intelligence Scale for Children Revised - Performance IQ
	WISC-R Verbal IQ	Wechsler Intelligence Scale for Children Revised - Verbal IQ
<b>Attention/Working Memory</b>		
	2-back	n-back task - 2-back accuracy
	3-back	n-back task - 3-back accuracy
	CANTAB Spatial Span Length	Cambridge Neuropsychological Test Automated Battery - Spatial Span Length
	CANTAB Spatial Working Memory	Cambridge Neuropsychological Test Automated Battery - Spatial Working Memory
	IGD Working Memory Score	Inventory for Memory Diagnostics - Working Memory Score
	PMT cards sorted	Prospective Memory Task - number of cards sorted
	RVIP detections	Rapid Visual Information Processing Task - mean detections per minute
	RVIP false alarms	Rapid Visual Information Processing Task - false alarms

Domain	Abbreviation	Test
	TMT part A	Trail Making Test - Part A
	WAIS-R Arithmetic	Wechsler Adult Intelligence Scale Revised - Arithmetic
	WAIS-R Digit Span	Wechsler Adult Intelligence Scale Revised - Digit Span
	WAIS-R Orientation	Wechsler Adult Intelligence Scale Revised - Orientation
	WISC-R Arithmetic	Wechsler Intelligence Scale for Children Revised - Arithmetic
	WISC-R Digit Span	Wechsler Intelligence Scale for Children Revised - Digit Span
	WMS-III Digits Backward	Wechsler Memory Scale Third Edition - Digits Backward
	WMS-III Letter Number Span	Wechsler Memory Scale, Third Edition - Letter Number Span
	WMS-III Letter Number Span	Wechsler Memory Scale, Third Edition - Spatial Span
	WMS-III Spatial Span	Wechsler Memory Scale Revised - Backward Digit Span
	WMS-R Concentration/Attention Score	Wechsler Memory Scale Revised - Concentration and Attention Score
<b>Executive Functioning</b>		
	CA validity effect	Covert Attention Task Validity Effect
	CANTAB set-shifting errors	Cambridge Neuropsychological Test Automated Battery - Intra-extra dimensional set shifting errors
	COWAT	Controlled Oral Word Association Test
	DKEFS Design Fluency switching	Delis-Kaplan Executive Function System - Design Fluency, switching score
	DKEFS Letter Fluency	Delis-Kaplan Executive Function System - Letter Fluency
	DKEFS TMT switching	Delis-Kaplan Executive Function System - Trail Making Test, switching score
	Kramer Card Sorting	Kramer Card Sorting - number of correct concepts
	MSIT Incongruent RT	Multi-Source Interference Task - Incongruent Trials RT
	Nonverbal Fluency	Nonverbal Fluency
	Stroop interference condition	Stroop interference condition
	TMT part B	Trail Making Test - Part B
	Verbal Fluency-FAS	Verbal Fluency - letters F-A-S
	Verbal Fluency-S words	Verbal Fluency - S words
	WISC-IV Similarities	Wechsler Intelligence Scale for Children Fourth Edition - Similarities
	WISC-IV Matrix Reasoning	Wechsler Intelligence Scale for Children Fourth Edition - Matrix Reasoning
	WISC-R Similarities	Wechsler Intelligence Scale for Children Revised - Similarities
	WISC-R Mazes	Wechsler Intelligence Scale for Children Revised - Mazes
<b>Language</b>		
	BNT	Boston Naming Test

Domain	Abbreviation	Test
	CDIIT Language	Comprehensive Development Inventory for Infants and Toddlers - Language
	Spot-the-Word	Spot-the-Word Task
	SRB Synonyms	Dureman-Sälde battery - Synonyms
	WAIS-R Information	Wechsler Adult Intelligence Scale Revised - Information
	WISC-IV Vocabulary	Wechsler Intelligence Scale for Children Revised - Vocabulary
	WISC-R Comprehension	Wechsler Intelligence Scale for Children Revised - Comprehension
	WISC-R Information	Wechsler Intelligence Scale for Children Revised - Information
<b>Memory</b>	AVLT total learning	Auditory-Verbal Learning Test - total learning
	AVLT long-term recall	Auditory-Verbal Learning Test - long-term recall
	BVMT-R total learning	Brief Visuospatial Memory Test Revised - total learning
	CANTAB Paired Associate Learning	Cambridge Neuropsychological Test Automated Battery - paired associate learning
	CANTAB Pattern Recognition	Cambridge Neuropsychological Test Automated Battery - paired recognition memory
	CANTAB Spatial Recognition	Cambridge Neuropsychological Test Automated Battery - spatial recognition memory
	Complex Figure Test recall	Complex Figure Test - recall
	CVLT I immediate Recall	California Verbal Learning Test, immediate recall
	CVLT I delayed Recall	California Verbal Learning Test, delayed recall
	CVLT-German immediate recall	California Verbal Learning Test - German, immediate recall
	CVLT-German trial 1 immediate recall	California Verbal Learning Test - German, Trial 1 immediate recall
	CVLT-German short delay recall	California Verbal Learning Test - German, short delay recall
	CVLT-German delayed recall	California Verbal Learning Test - German, delayed recall
	CVLT-II Trials 1-5	California Verbal Learning Test-II - Trials 1-5 total learning
	CVLT-II long delay free recall	California Verbal Learning Test-II - long delay free recall
	Episodic Memory Task immediate recall	Episodic Memory Task - immediate written recall (created by authors) <sup>b</sup>
	fMRI Face-Name immediate retrieval	fMRI Face-Name paradigm - immediate retrieval
	fMRI Face-Name delayed retrieval	fMRI Face-Name paradigm - delayed retrieval
	fMRI neutral scenes encoded	fMRI Neutral Scenes - percent encoded
	fMRI neutral scenes retrieved	fMRI Neutral Scenes - percent retrieved
	fMRI Picture Encoding false alarms	fMRI Picture Encoding Task - subsequent item memory false alarm rate
	fMRI Picture Encoding hits	fMRI Picture Encoding Task - subsequent item memory hit rate
	fMRI post-scan memory test	fMRI post-scan memory test - global performance

Domain	Abbreviation	Test
	fMRI Spatial Memory drop error	fMRI Spatial Memory Paradigm - degree of drop error
	IGD learning ability	Inventory for Memory Diagnostics - learning ability score
	IGD delayed recall	Inventory for Memory Diagnostics - delayed recall score
	PMT detections	Prospective Memory Task - detections
	VAT cued recall	Verbal Associative Learning Test – cued recall
	VAT recognition	Verbal Associative Learning Test – recognition
	WMS Logical Memory I	Wechsler Memory Scale (unknown version) - Logical Memory I
	WMS Logical Memory II	Wechsler Memory Scale (unknown version) - Logical Memory II
	WMS Visual Reproduction I	Wechsler Memory Scale (unknown version) - Visual Reproduction I
	WMS Visual Reproduction II	Wechsler Memory Scale (unknown version) - Visual Reproduction II
	WMS-R Verbal Memory	Wechsler Memory Scale Revised – Verbal Memory score
	WMS-R Visual Memory	Wechsler Memory Scale Revised – Visual Memory score
	WMS-R Delayed Recall	Wechsler Memory Scale Revised – Delayed Recall score
	WMS-R General Memory	Wechsler Memory Scale Revised – General Memory score
	WMS-R Logical Memory I	Wechsler Memory Scale Revised - Logical Memory I
	WMS-R Logical Memory II	Wechsler Memory Scale Revised - Logical Memory II
	<b>Processing Speed</b>	
	CANTAB Choice RT	Cambridge Neuropsychological Test Automated Battery - Choice RT
	CANTAB Rapid Visual Info Processing	Cambridge Neuropsychological Test Automated Battery - Rapid Visual Information Processing Task
	Simple RT	Simple RT
	Choice RT	Choice RT
	Letter Digit Substitution Test	Letter Digit Substitution Test
	MSIT Congruent Trials RT	Multi-Source Interference Task - congruent trials RT
	Processing speed composite	Sorting Task and Visual Attention Task - RT, combined z-scores
	Symbol-Digit Modalities Test	Symbol-Digit Modalities Test
	WISC-R Coding	Wechsler Intelligence Scale for Children Revised - Coding
	<b>Visuospatial Abilities</b>	
	Complex Figure Test Copy	Complex Figure Test - copy
	Luria Mental Rotation	Luria Mental Rotation
	RCFT Copy	Rey Complex Figure Test - copy
	WAIS-R Block Design	Wechsler Adult Intelligence Scale Revised - Block Design



Domain	Abbreviation	Test
	WISC-R Block Design	Wechsler Intelligence Scale for Children Fourth Edition - Block Design
	WISC-R Block Design	Wechsler Intelligence Scale for Children Revised - Block Design
	WISC-R Object Assembly	Wechsler Intelligence Scale for Children Revised - Object Assembly
	WISC-R Picture Arrangement	Wechsler Intelligence Scale for Children Revised - Picture Arrangement
	WISC-R Picture Completion	Wechsler Intelligence Scale for Children Revised - Picture Completion

<sup>a</sup> Authors (Green et al., 2014; Shaw et al., 2007) do not cite source of IQ score.

<sup>b</sup> This task was created by Dowell et al. (2013).

**Table 2.**

Demographic data for participants in APOE  $\epsilon 4$  versus APOE non- $\epsilon 4$  analysis.

Study	Study Characteristics		N		Age		Sex		Education				Education Metric			
	Recruitment	Age Range	Genotype Breakdown	$\epsilon 4$	non- $\epsilon 4$	M	SD	$\epsilon 4$	non- $\epsilon 4$	%F	%F	M		SD	M	SD
Alexopoulos et al. (2011)	College-aged		$\epsilon 2/2, \epsilon 2/3$ vs. $\epsilon 3/4, \epsilon 4/4$	16	17	24.20	4.10	24.70	3.20	56%	71%	16.56	2.07	17.35	2.69	Years
Bloss et al. (2008)	11-16		$\epsilon 2/3, 3/3$ vs. $\epsilon 3/4, \epsilon 4/4$	24	85	13.42	1.40	13.42	1.22	50%	56%	16.46	2.17	16.35	2.09	Mother-years
Bloss et al. (2008)	11-16		$\epsilon 2/3, 3/3$ vs. $\epsilon 3/4, \epsilon 4/4$	24	85	13.42	1.40	13.42	1.22	50%	56%	16.46	2.17	16.35	2.09	Mother-years
Bloss et al. (2010)	11-16		$\epsilon 3/3$ vs. $\epsilon 3/4, \epsilon 4/4$	33	90	13.34	1.32	13.28	1.30	55%	61%	16.46	2.17	16.28	2.15	Mother-years
Bunce et al. (2011)	20-24		$\epsilon 3/3$ vs. $\epsilon 3/4, \epsilon 4/4$	530	1291	(20-24)	-	(20-24)	-	50%	53%	14.56	1.59	14.56	1.55	Years
Bunce et al. (2014)	20-24		$\epsilon 2/2, \epsilon 2/3$ vs. $\epsilon 3/4, \epsilon 4/4$	426	189	(20-24)	-	(20-24)	-	-	-	-	-	-	-	-
Calderon-Garciduenas et al. (2016)	Children		$\epsilon 3/3$ vs. $\epsilon 3/4$	36	69	12.70	6.70	11.89	4.10	53%	43%	11.62	1.90	11.07	2.30	Mother-years
Calderon-Garciduenas et al. (2016)	Children		$\epsilon 3/3$ vs. $\epsilon 3/4$	36	69	12.70	6.70	11.89	4.10	53%	43%	11.62	1.90	11.07	2.30	Mother-years
Calderon-Garciduenas et al. (2015)	Children		$\epsilon 3/3$ vs. $\epsilon 3/4, \epsilon 4/4$	22	28	13.62	4.80	13.36	5.00	50%	43%	11.62	1.74	11.07	2.12	Mother-years
Dell'Acqua et al., 2015	14 year olds		$\epsilon 3/3$ vs. $\epsilon 3/4$	114	372	14.40	0.50	14.40	0.50	41%	45%	-	-	-	-	-
Dennis et al. (2010)	Young Adult		$\epsilon 2/3, \epsilon 3/3$ vs. $\epsilon 3/4, \epsilon 4/4$	12	12	21.80	3.30	20.80	2.90	58%	75%	-	-	-	-	-
Dowell et al. (2013)	18-30		$\epsilon 3/3$ vs. $\epsilon 3/4, \epsilon 4/4$	21	20	21.40	2.20	20.90	1.40	62%	70%	-	-	-	-	-
Evans et al. (2014)	18-30		$\epsilon 3/3$ vs. $\epsilon 3/4, \epsilon 4/4$	21	20	21.40	2.20	20.90	1.40	62%	70%	15.10	0.20	15.10	0.30	Years

Study	Study Characteristics				Age				Sex				Education				Education Metric
	Recruitment	Age Range	Genotype Breakdown		e4		non-e4		e4		non-e4		e4		non-e4		
			M	SD	M	SD	M	SD	%F	%M	M	SD	M	SD	M	SD	
Filippini et al. (2009)	20-35	e3/3 vs. e3/4, e4/4	18	18	28.40	4.90	28.60	3.90	39%	44%	19.60	2.00	19.50	1.50	Years		
Green et al. (2014) CLU-C sample <sup>b</sup>	College-aged	e3/3 vs. e3/4, e4/4	23	16	24.00	5.49	25.25	5.87	17%	6%	–	–	–	–	–		
Jorn et al. (2007)	20-24	e2/3, e3/3 vs. e3/4	517	1524	(20-24)	–	(20-24)	–	–	–	–	–	–	–	–		
Kunz et al. (2015)	18-30	e3/3 vs. e3/4	38	37	22.34	0.45	22.76	0.49	53%	51%	16.05	0.37	16.19	0.38	Years		
Matura et al. (2016)	20-39	e3/3 vs. e3/4, e4/4	25	25	26.75	5.31	25.83	3.61	44%	44%	17.67	2.12	17.58	2.43	Years		
Matura et al. (2014)	20-38	e3/3 vs. e3/4, e4/4	25	25	26.60	5.20	26.20	4.10	44%	44%	17.70	2.10	17.60	2.60	Years		
Mondadori et al. (2007)	Young Adult	e2/3, e3/3 vs. e3/4, e4/4	13	10	22.60	3.50	21.60	1.70	46%	60%	14.30	1.70	13.80	1.50	Years		
Ng et al. (2013) High Mercury <sup>c</sup>	Age 2	e3/3 vs. e3/4, e4/4	14	59	2.00	0.00	2.00	0.00	50%	39%	50%	–	57.6%	–	Mother %college edu		
Ng et al. (2013) Low Mercury <sup>c</sup>	Age 2	e3/3 vs. e3/4, e4/4	12	51	2.00	0.00	2.00	0.00	67%	49%	50%	–	56.9%	–	Mother %college edu		
Nichols et al. (2012) scanned cohort	19-40	e3/3 vs. e3/4	23	57	27.00	4.90	27.00	5.30	40%	58%	17.00	1.50	17.00	2.40	Years		
Nichols et al. (2012) non-scanned cohort	18-40	e3/3 vs. e3/4	48	122	(18-40)	–	(18-40)	–	67%	54%	–	–	–	–	–		
O'Dwyer et al. (2012)	20-38	e3/3 vs. e3/4, e4/4	22	22	26.90	5.30	26.70	4.00	41%	41%	17.00	4.30	16.80	4.50	Years		
Reiman et al. (2004)	20-39	e2/3, e3/3 vs. e3/4	12	15	30.70	5.40	31.20	5.00	75%	80%	16.00	1.70	16.10	1.50	Years		
Ruiz et al. (2010)	13-18.5	e2/3, e3/3 vs. e3/4	76	336	NA	NA	NA	NA	49%	51%	–	–	–	–	–		
Shaw et al. (2007)	< 21yo	e3/3 vs. e3/4, e4/4	65	145	NA	NA	NA	NA	51%	42%	–	–	–	–	–		

Study	Study Characteristics			Age			Sex			Education			Education Metric			
	Recruitment	Age Range	Genotype Breakdown	$\epsilon 4$	non- $\epsilon 4$	$\epsilon 4$	$\epsilon 4$	non- $\epsilon 4$	%F	%F	$\epsilon 4$	non- $\epsilon 4$		$\epsilon 4$	non- $\epsilon 4$	$SD$
Sinclair et al. (2015)	18		$\epsilon 3/3$ vs. $\epsilon 3/4$	542	1215	18.00	0.00	18.00	0.00	51%	56%	23.2%	20.9%	–	–	Mother % w/ degree
Stening et al. (2016) Female	19-35		$\epsilon 3/3$ vs. $\epsilon 3/4$ , $\epsilon 4/4$	16	39	23.20	3.20	23.60	3.60	100%	100%	14.60	1.90	14.80	1.90	Years
Stening et al. (2016) Male	19-35		$\epsilon 3/3$ vs. $\epsilon 3/4$ , $\epsilon 4/4$	19	36	25.30	3.90	23.60	2.80	0%	0%	16.10	1.80	14.70	1.30	Years
Suri et al. (2015)	20-40		$\epsilon 3/3$ vs. $\epsilon 3/4$ , $\epsilon 4/4$	18	17	23.88	4.75	24.11	4.96	56%	53%	17.05	2.18	17.50	2.89	Years
Wierenga et al. (2013)	College-aged		$\epsilon 3/3$ vs. $\epsilon 3/4$ , $\epsilon 4/4$	15	15	23.60	3.10	23.30	3.00	80%	53%	14.90	0.30	15.00	0.50	Years
Zhang et al. (2015)	16-39		$\epsilon 3/3$ vs. $\epsilon 3/4$ , $\epsilon 4/4$	47	200	26.90	5.90	27.44	6.40	55%	47%	11.30	3.75	11.02	3.59	Years

Note: n = study sample size; sd = standard deviation, M = mean, edu = education, %F = percent female;  $\epsilon 4$  = at least one Apolipoprotein  $\epsilon 4$  allele; non- $\epsilon 4$  = Apolipoprotein  $\epsilon 2$  and/or  $\epsilon 3$  carriers.

<sup>a</sup> Study reports cognitive data separately by subgroup but demographics are reported for full sample.

<sup>b</sup> Study examines CLU-C and non-CLU-C; only CLU-C was considered because CLU-nonC  $\epsilon 4$  group only included three participants.

<sup>c</sup> Study of toddlers who were exposed to mercury while in the womb.